Efortless BioPharma Update’s Post

Efortless.bio Today! 1. MorphoSys's phase 3 trial of CPI-0610 shows positive results in treating Myelofibrosis MorphoSys today announced topline results of the phase 3 study of CPI-0610(Pelabresib) for the treatment of Myelofibrosis (MF) https://lnkd.in/gVT7_GYu 2. Plus Therapeutics' phase 2 trial of rhenium(186Re) obisbemeda shows longer median overall survival in glioblastoma patients Plus Therapeutics today announced interim results of the phase 2 study of rhenium(186Re) obisbemeda, a radioconjugate, in patients with glioblastoma(rGBM). The study showed a median overall survival(mOS) of 13 months in a group of 15 patients, which was 63% longer than the current standard of care. https://lnkd.in/gS22AGTq 3. Agios Pharmaceuticals's phase 2a trial in LR-MDS demonstrates positive results for anemia treatment Agios Pharmaceuticals today announced interim results of the phase 2a study of AG-946, a potential treatment for anemia in lower-risk myelodysplastic syndromes(LR-MDS). The primary endpoints, including transfusion independence and hemoglobin response, showed promising results in a subset of patients. https://lnkd.in/g7rkU5zX If you would like a free market report on an indication you are interested in, please let me know in any way and I will provide it within 24 hours.

Today's Efortless BioPharma Update brings you: 1. Vertex Pharmaceuticals' topline results of the phase 2 study of their small molecule drug VX-548 for diabetic peripheral neuropathy (DPN). The study met the primary endpoint with statistically significant and clinically meaningful reductions in the weekly average of daily pain intensity on a Numeric Pain Rating Scale (NPRS) at Week 12. 👉 https://lnkd.in/gD9UqraC 2. Shattuck Labs' topline results of their phase 1a/b study of SL-172154, a therapeutic protein, for higher-risk myelodysplastic syndromes (HR-MDS) and relapsed/refractory acute myeloid leukemia (R/R AML), 👉 https://lnkd.in/gRmRrffs 3. Black Diamond Therapeutics' topline results of the BDTX-1535 phase 1 trial in Glioblastoma (GBM). Of the 22 patients evaluable for efficacy, several patients showed prolonged progression-free survival, surpassing historical benchmarks for this patient population. 👉 https://lnkd.in/g_yaVZ4j

Avidity Biosciences, Inc. has moved forward with a Phase 2 study of AOC 1044, which consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with phosphorodiamidate morpholino oligomers targeting exon 44. The study, which is enrolling by invitation, is designed to evaluate the pharmacodynamic effect of AOC 1044 on dystrophin protein production in skeletal muscle, as well as the long-term safety, tolerability, pharmacokinetics, and exploratory efficacy of AOC 1044, in Duchenne muscular dystrophy participants with mutations amenable to exon44 skipping. #mabs https://lnkd.in/eCpDiG49

Fascinated by advancements in clinical trials? Explore our in-depth analysis of evolving RTSM and IRT technologies. Discover their critical role in optimizing trial accuracy and patient-centricity in the healthcare landscape. Learn more: https://lnkd.in/gR-hs9qN

In the intricate dance of clinical research, 'efficacy' leads the way. 💡 It's the measure of a treatment's potential in perfect conditions. But how does it fare in the real world? That's where effectiveness steps in. Our latest blog post breaks down these crucial concepts. Perfect read for healthcare professionals and enthusiasts alike! #ClinicalEfficacy #DrugDevelopment #HealthcareIndustry

Expert opinions revealed for upcoming developments in clinical research - areas expected to undergo substantial growth in 2024. In this article, experts share their perspectives illuminating the dynamic landscape of clinical trials. From cutting-edge treatments to pioneering advancements, staying ahead in this evolving field is imperative. Comprehending these trends is essential for success in the healthcare realm.  #ClinicalResearch #InnovationInHealthcare #TherapeuticsTrends #LinkedInInsights https://lnkd.in/espWX7am

This nerd has been stressing since Friday because she couldn't get into the #ACR23 platform until yesterday. Nevertheless, it is exciting to be completing my third year at the American College of Rheumatology Convergence with the Spondylitis Association of America. I just completed my first giant thread on X which is where 'all things rheumatology' happen. I'm posting under globetrotteri for this #rheumatology convergence. I love this year's overarching theme as it is a topic that I've been writing about for years here in Taiwan. ACR22's overarching theme was climate change and delivering care in adverse settings. This year's summit is about drug discovery, delivery and accessibility in low- to middle-income countries. TOPIC: 📢 Global Summit: Forging Innovative Partnerships to Expand Global Access to Essential Medicines "Despite transformational advances in drug discovery & development, nearly two billion people around the world go without regular access to medications needed to maintain health and to prevent mortality." This presentation discusses high-level stakeholders and factors that impact medication access and affordability. Let's learn about the current state of access to medications globally in this session and how to identify stakeholders. It also includes the factors that impact access and affordability of medicines around the world. We'll also learn about innovative strategies led by Access to Medicine Foundation to engage pharmaceutical companies to increase access to medications in areas of need. ♿ I'd also like to mention that virtual/hybrid health summits for people like me are priceless. I can't attend them in person due to being disabled, but the real benefit is that livestreams and on demand presentations allow us to learn at our own pace without having to rush from room to room in a convention center. #Spondylitis Read the full thread here: https://lnkd.in/gspgPais Or wait for my release on My Several Worlds when I do my event sum-up.

✨ From the latest in medical advancements to pivotal policy shifts, the landscape of healthcare is evolving at an unprecedented pace. Here's a sneak peek at what this week's wrap-up covers: 🧬 Innovative research discoveries and the latest breakthroughs that are setting new standards in medical science. 📊 Policy and regulation updates and changes that could impact your work and business. 🌐 Global health initiatives and collaborations that are reshaping healthcare delivery across borders. 💡 Tech integration in medicine that is revolutionizing patient care. Our comprehensive weekly wrap-up delves deeper into these topics, offering curated news you won't find anywhere else. 🔗 Check out the full wrap-up below. 👇

Key clinical trial for CIDP Patients to start very soon.

According to recent stats, inefficiencies in clinical research can cost up to $1.2 million per day. This eye-opening article explores proven methods to mitigate these costs and streamline operations, ultimately expediting the delivery of life-saving treatments. Let's heed these insights and collaborate towards a future where every dollar and every day in research counts towards improving patient outcomes. https://lnkd.in/gEjXZ488